Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
LAMOTRIGINE (UNII: U3H27498KS) (LAMOTRIGINE - UNII:U3H27498KS)
Clinical Solutions Wholesale, LLC
LAMOTRIGINE
LAMOTRIGINE 25 mg
ORAL
PRESCRIPTION DRUG
Adjunctive Therapy Lamotrigine tablets, USP is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: Monotherapy Lamotrigine tablets, USP is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets, USP have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. Lamotrigine tablets, USP is indicated for the maintenance treatment of Bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy Lamotrigine tablet
Lamotrigine Tablets, USP 25 mg, light pink, capsule-shaped, uncoated, biconvex tablet with "C148" debossed on one side and central breakline on the other side, supplied in bottles of 30 (NDC 69097-148-02), bottles of 100 (NDC 69097-148-07), bottles of 500 (NDC 69097-148-12), bottles of 1000 (NDC 69097-148-15), and blister cards of 30 (NDC 58118-2148-8). 100 mg, light pink, capsule-shaped, uncoated, biconvex tablet with "C149" debossed on one side and central breakline on the other side, supplied in bottles of 30 (NDC 69097-149-02), bottles of 100 (NDC 69097-149-07), bottles of 500 (NDC 69097-149-12) and bottles of 1000 (NDC 69097-149-15). 150 mg, light pink, capsule-shaped, uncoated, biconvex tablet with "C151" debossed on one side and central breakline on the other side, supplied in bottles of 30 (NDC 69097-151-02), bottles of 60 (NDC 69097-151-03), bottles of 500 (NDC 69097-151-12) and bottles of 1000 (NDC 69097-151-15). 200 mg, light pink, capsule-shaped, uncoated, biconvex tablet with "C152" debossed on one side and central breakline on the other side, supplied in bottles of 30 (NDC 69097-152-02), bottles of 60 (NDC 69097-152-03), bottles of 500 (NDC 69097-152-12) and bottles of 1000 (NDC 69097-152-15). Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature] in a dry place and protect from light.
Abbreviated New Drug Application
LAMOTRIGINE- LAMOTRIGINE TABLET Clinical Solutions Wholesale, LLC ---------- MEDICATION GUIDE Lamotrigine Tablets, USP (la moe'tri jeen) What is the most important information I should know about lamotrigine tablets, USP? 1. Lamotrigine tablets, USP may cause a serious skin rash that may cause you to be hospitalized or even cause death. There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with lamotrigine tablets, USP but is more likely to happen within the first 2 to 8 weeks of treatment. Children and teenagers between 2 and 17 years have a higher chance of getting this serious skin rash while taking lamotrigine tablets, USP. The risk of getting a serious skin rash is higher if you: • take lamotrigine tablets, USP while taking valproate [DEPAKENE ®(valproic acid) or DEPAKOTE ®(divalproex sodium)]. • take a higher starting dose of lamotrigine tablets, USP than your healthcare provider prescribed • increase your dose of lamotrigine tablets, USP faster than prescribed. Call your healthcare provider right away if you have any of the following: • a skin rash • blistering or peeling of your skin • hives • painful sores in your mouth or around your eyes These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking lamotrigine tablets, USP. 2. Other serious reactions, including serious blood problems or liver problems. Lamotrigine can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of these symptoms: • fever • frequent infections • severe muscle pain • swelling of your face, eyes, lips, or tongue • swollen lymph glands • unusual bruising or bleeding • weakness, fatigue • yellowing of your skin or the white part of Lire le document complet
LAMOTRIGINE- LAMOTRIGINE TABLET CLINICAL SOLUTIONS WHOLESALE, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LAMOTRIGINE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LAMOTRIGINE TABLETS, USP. LAMOTRIGINE TABLETS, USP, FOR ORAL USE INITIAL U.S. APPROVAL:1994 WARNING: SERIOUS SKIN RASHES _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CASES OF LIFE-THREATENING SERIOUS RASHES, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, AND/OR RASH-RELATED DEATH, HAVE BEEN CAUSED BY LAMOTRIGINE. THE RATE OF SERIOUS RASH IS GREATER IN PEDIATRIC PATIENTS THAN IN ADULTS. ADDITIONAL FACTORS THAT MAY INCREASE THE RISK OF RASH INC LUDE : COADMINISTRATION WITH VALPROATE EXCEEDING RECOMMENDED INITIAL DOSE OF LAMOTRIGINE EXCEEDING RECOMMENDED DOSE ESCALATION OF LAMOTRIGINE ( 5.1) BENIGN RASHES ARE ALSO CAUSED BY LAMOTRIGINE; HOWEVER, IT IS NOT POSSIBLE TO PREDICT WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. LAMOTRIGINE SHOULD BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. ( 5.1) RECENT MAJOR CHANGES Boxed Warning 5/2015 Indications and Usage, Bipolar Disorder ( 1.2) 5/2015 Warnings and Precautions, Serious Skin Rashes ( 5.1) 5/2015 Warnings and Precautions, Laboratory Tests ( 5.13) 5/2015 INDICATIONS AND USAGE Lamotrigine tablets, USP is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. ( 1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard thera Lire le document complet